Mill Creek Capital Advisors LLC Makes New Investment in Precigen, Inc. (NASDAQ:PGEN)

Mill Creek Capital Advisors LLC purchased a new position in Precigen, Inc. (NASDAQ:PGEN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 110,000 shares of the biotechnology company’s stock, valued at approximately $104,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. EntryPoint Capital LLC purchased a new position in Precigen in the first quarter worth $31,000. Traphagen Investment Advisors LLC bought a new position in shares of Precigen during the 3rd quarter valued at about $29,000. SG Americas Securities LLC lifted its position in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after buying an additional 13,823 shares during the last quarter. AQR Capital Management LLC boosted its stake in Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after buying an additional 18,097 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Precigen by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 25,681 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Wall Street Analysts Forecast Growth

PGEN has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Precigen in a report on Friday. StockNews.com raised shares of Precigen to a “sell” rating in a research note on Thursday, August 1st. Finally, JMP Securities reduced their price objective on Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.00.

Precigen Stock Performance

Shares of Precigen stock opened at $0.82 on Monday. Precigen, Inc. has a 52-week low of $0.78 and a 52-week high of $1.93. The company’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.24.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.